chronic migraine
Neurology · 2011–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| erenumab Prophylaxis of chronic migraine in adults who have experienced inadequate response, intolerance or contraindication to at least 3 prophylactic migraine… | Nov 2024 | Recommended with restriction | 51 individuals |
| atogepant Prophylaxis of chronic migraine or high frequency episodic migraine in adults who have experienced inadequate response, intolerance or contraindication to at… | Jul 2023 | Not recommended | input received Headache Australia · Migraine Australia |
| eptinezumab Treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic… | Jul 2022 | Recommended with restriction | 85 individuals Headache Australia · Migraine Australia · ANZ Headache Society |
| fremanezumab Chronic migraine in patients with inadequate response, intolerance or contraindication to at least three prophylactic migraine medications, who have… | Mar 2022 | Recommended | 18 individuals Migraine Australia |
| fremanezumab Continuing treatment of chronic migraine in patients who have achieved and maintained a 50% or greater reduction from baseline in the number of migraine days… | Mar 2022 | Recommended with restriction | 1 individuals Migraine Australia |
| fremanezumab Preventive treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or a contraindication to at least three… | Mar 2020 | Recommended with restriction | no section in document |
| galcanezumab Prophylaxis of chronic migraine in adults who have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic… | Nov 2020 | Recommended with restriction | 186 individuals Migraine Australia |
| galcanezumab Treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic… | Jul 2019 | Recommended with restriction | 56 individuals Headache Australia |
| erenumab Prophylaxis of migraine in adults with chronic migraine who have experienced an inadequate response, intolerance or a contraindication to at least three… | Mar 2019 | Not recommended | 258 individuals Headache Australia |
| fremanezumab Treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or contraindication to at least three prophylactic migraine… | Nov 2019 | Deferred | 57 individuals Migraine Australia |
| erenumab Prophylaxis of chronic migraine in adults who have experienced inadequate response, intolerance or contraindication to at least three prophylactic migraine… | Jul 2018 | Not recommended | input received |
| botulinum toxin type A Prophylaxis of headaches in adult patients with chronic migraine who have experienced an average of 15 or more headache days per month (with at least 8 days of… | Mar 2018 | Not recommended | 4 individuals |
| botulinum toxin type A Prophylaxis of headaches in adults with chronic migraine who have experienced an average of 15 or more headache days per month (with at least 8 days of… | Jul 2013 | Recommended with restriction | unclear |
| botulinum toxin type A Prophylaxis of headaches in adult patients with chronic migraine (headache on at least 15 days per month of which at least 8 days are with migraine) who have… | Jul 2012 | Recommended | unclear |
| botulinum toxin type A Prophylaxis of headaches in adults with chronic migraine (headache on at least 15 days per month of which at least 8 days are with migraine) who have failed or… | Nov 2011 | Not recommended | unclear |
Who spoke
Migraine Australia · Headache Australia · ANZ Headache Society
What the PBS pays
$211M in government benefit over 2024–25, across 380,201 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| fremanezumab | $80M |
| botulinum toxin type A | $72.8M |
| galcanezumab | $48.2M |
| eptinezumab | $9.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| botulinum toxin type aBotulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | recommended restricted | 2012-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 11 of 12 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.